Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).

UMIN ID: UMIN000000492

Registered date:01/10/2006

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)
• Date of first enrollment: 2006/08/01
• Target sample size: 160
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Spironolactorne
No Spironolactorne

Outcome(s)

• Primary Outcome: Parameters of CVD, occurrence and/or augmentation of the other complications in peritoneal dialysis (PD) patients
• Secondary Outcome: residual renal functional examination, peritoneal functional examination

Key inclusion & exclusion criteria

• Age minimum: 18years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: Should be excluded even if one of them would be positive; Patients under 18, older than 80. Patients with anemia whose Hb is less than 9 g/dl. Patients treated for more than 5 years after initiation of dialysis. Patients with heart failure of NYHA III, IV. Patients with pregnancy or the suspected. Patients treated with acid-base fluid dialysis.

Related Information

• Primary Sponsor: Nagoya University
• Source(s) of Monetary Support: Nagoya University, Nephrology and Renal Replacement Therapy.